Controlled release oral dosage form

• US 20040005359A1
• Filed: 06/27/2002
• Published: 01/08/2004
• Est. Priority Date: 06/27/2002
• Status: Abandoned Application

• Current Assignee: Andrx Pharmaceuticals LLC (Abbvie Incorporated)
• Original Assignee: Andrx Pharmaceuticals LLC (Abbvie Incorporated)
• Inventors: Chen, Chih Ming, Cheng, Xiu Xiu, Tian, Dacheng
• Application Number:
  US10/183,776
• Publication Number:
  US 20040005359A1
• Time in Patent Office: Days
• US Class Current: 424/471
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 31/554 having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

A sustained-release pharmaceutical preparation is disclosed in which a calcium channel blocker, preferably verapamil, core is surrounded by an optional seal coat layer and a water-insoluble coating.

Claims

1. A sustained-release pharmaceutical preparation comprising:

(a) a core comprising;

(i) a therapeutically effective dose of a calcium channel blocker;

(ii) an osmopolymer having a high and/or low molecular weight;

(iii) optionally, an osmagent;

(iv) an organic acid;

(v) optionally, a disintegrant,

(vi) optionally, a lubricant; and

(vii) optionally, at least one pharmaceutically acceptable inert ingredient,

(b) optionally, a seal coating surrounding said core, and;

(c) a water-insoluble coating comprising;

(i) a water insoluble polymer;

(ii) a plasticizer; and

(iii) a dissolution enhancing agent.

2. The sustained-release pharmaceutical preparation as defined in claim 1 wherein the calcium channel blocking agent is selected from the group consisting of verapamil, diltiazem, amlodipine, nicardipine, nimodipine, nilvadipine, flunarizine, norverapamil, nitredipine, cinnarizine, nifedipine, nisoldipine, fendiline, isradipine, feldopine, or their pharmaceutically acceptable derivatives, salts and steroisomers thereof.

3. The sustained-release pharmaceutical preparation as defined in claim 2 wherein the calcium channel blocker is verapamil or a pharmaceutically acceptable derivative thereof.

4. The pharmaceutical preparation of claim 1 wherein the disintegrant is selected from the group consisting of alginic acid, carboxymethylcellulose, croscarmelose sodium, crospovidone, povidone, sodium alginate and sodium starch glycolate.

5. The pharmaceutical preparation of claim 1 wherein the osmopolymer is a combination of high molecular weight osmopolymer and low molecular weight osmopolymer.

6. The pharmaceutical preparation of claim 5 wherein the low molecular weight osmopolymer is selected from the group consisting of polyethylene oxides, said osmopolymer having a molecular weight between 8,500 to 600,000.

7. The pharmaceutical preparation of claim 5 wherein the high molecular weight osmopolymer is selected from the group consisting of polyethylene oxides, said osmopolymer having a molecular weight over 4,000,000.

8. The pharmaceutical preparation of claim 5 wherein the low molecular weight osmopolymer is Polyox N-80.

9. The pharmaceutical preparation of claim 5 wherein the high molecular weight osmopolymer is Polyox coagulant.

10. The pharmaceutical preparation of claim 5 wherein the ratio of the amount of weight percent of the high molecular weight osmopolymer to low molecular weight osmopolymer is about 1:

1.24.

11. The pharmaceutical preparation of claim 1 wherein the osmagent is selected from the group of organic and inorganic salts.

12. The pharmaceutical preparation in claim 5 wherein the tablet lubricant is selected from the group consisting of glycerol monostearates, magnesium stearate, calcium stearate, stearic acid and monoglycerides.

13. The pharmaceutical preparation of claim 1 wherein the osmagent is sodium chloride.

14. The pharmaceutical preparation of claim 1 wherein the organic acid is selected from the group consisting of adipic acid, ascorbic acid, citric acid, fumaric acid, malic acid, succinic acid, tartaric acid or a mixture thereof.

15. The pharmaceutical preparation of claim 1 wherein the organic acid is fumaric acid.

16. The pharmaceutical preparation in claim 1 wherein the polymer in the water insoluble coating is selected from the group consisting of cellulose polymers.

17. The pharmaceutical preparation of claim 16 wherein the cellulose polymer selected is cellulose acetate.

18. The pharmaceutical preparation in claim 17 wherein the amount of cellulose acetate in the semipermeable coating is greater than about 60 wt %.

19. The pharmaceutical preparation in claim 1 wherein the plasticizers comprise 10-20% of the water-insoluble coating.

20. The pharmaceutical preparation in claim 1 wherein the plasticizer is a combination of plasticizers wherein one is an organic ester.

21. The pharmaceutical preparation according to claim 20 wherein the combination of plasticizers is 1:

1.

22. The pharmaceutical preparation according to claim 20 wherein the organic ester of plasticizer is triacetin.

23. The pharmaceutical preparation according to claim 1 where the dissolution enhancing agent is a polyethylene glycol having a molecular weight range of about 100 to 7500.

24. The pharmaceutical preparation according to claim 1 wherein the plasticizer is PEG 400.

25. The sustained-release pharmaceutical preparation as defined in claim 1 wherein the core comprises:

30-50% of the calcium channel blocker;

2-10% of the organic acid;

10-35% of the low molecular weight osmopolymer;

10-20% of the high molecular weight osmopolymer;

2-10% of the disintegrant;

2-10% of the osmagent;

0.1-2% of the lubricant.

26. The sustained-release pharmaceutical preparation as defined in claim 25 wherein the core comprises:

35-45% of the calcium channel blocker;

4-8% of the organic acid;

15-25% of the low molecular weight osmopolymer;

13-18% of the high molecular weight osmopolymer;

3-6% of the disintegrant;

3-8% of the water soluble osmotic agent;

0.5-1.5% of the lubricant.

27. The pharmaceutical preparation according to claim 26 with at least one exit means connecting the core with the exterior of the sustained release dosage formulation.

28. The pharmaceutical preparation according to claim 1 wherein the semipermeable coating consists essentially of:

70-80% cellulose acetate;

3-10% triacetin;

3-10% PEG 400; and

10-20% sugar.

29. The sustained-release pharmaceutical formulation as defined in claim 1 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in simulated intestinal fluid (pH 6.8 buffer) at 37°

C.;

after 2 hours 0-25% of the drug is released;

after 4 hours 10-50% of the drug is released;

after 8 hours 30-80% of the drug is released;

not less than 50% of the drug is released after 12 hours;

not less than 60% of the drug is released after 16 hours.

30. The sustained-release pharmaceutical formulation as defined in claim 1 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in simulated intestinal fluid (pH 6.8 buffer) at 37°

C.;

after 2 hours 5-20% of the drug is released;

after 4 hours 15-40% of the drug is released;

after 8 hours 40-70% of the drug is released;

not less than 55% of the drug is released after 12 hours;

not less than 65% of the drug is released after 16 hours.

31. The sustained-release pharmaceutical formulation as defined in claim 1 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in simulated gastric fluid (pH 1.2) at 37°

C.;

after 2 hours 0-25% of the drug is released;

after 4 hours 10-40% of the drug is released;

after 8 hours 40-75% of the drug is released;

not less than 50% of the drug is released after 12 hours;

not less than 65% of the drug is released after 16 hours.

32. The sustained-release pharmaceutical formulation as defined in claim 1 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in simulated gastric fluid (pH 1.2) at 37°

C.;

after 2 hours 5-20% of the drug is released;

after 4 hours 15-35% of the drug is released;

after 8 hours 50-65% of the drug is released;

not less than 60% of the drug is released after 12 hours;

not less than 65% of the drug is released after 16 hours.

33. The sustained-release pharmaceutical preparation wherein the core consists essentially of:

30-50% of the calcium channel blocker;

2-10% of the organic acid;

10-35% of the low molecular weight osmopolymer;

10-20% of the high molecular weight osmopolymer;

2-10% of the disintegrant;

2-10% of the osmagent;

0.1-2% of the lubricant; and

the semipermeable coating consists essentially of;

70-80% water-insoluble polymer;

3-20% plasticizer; and

10-20% dissolution enhancing agent.

34. The sustained-release pharmaceutical formulation as defined in claim 33 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in simulated intestinal fluid (pH 6.8 buffer) at 37°

C.;

after 2 hours 0-25% of the drug is released;

after 4 hours 10-50% of the drug is released;

after 8 hours 30-80% of the drug is released;

not less than 50% of the drug is released after 12 hours;

not less than 60% of the drug is released after 16 hours.

35. The sustained-release pharmaceutical formulation as defined in claim 33 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in simulated intestinal fluid (pH 6.8 buffer) at 37°

C.;

after 2 hours 5-20% of the drug is released;

after 4 hours 15-40% of the drug is released;

after 8 hours 40-70% of the drug is released;

not less than 55% of the drug is released after 12 hours;

not less than 65% of the drug is released after 16 hours.

36. The sustained-release pharmaceutical formulation as defined in claim 33 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in simulated gastric fluid (pH 1.2) at 37°

C.;

after 2 hours 0-25% of the drug is released;

after 4 hours 10-40% of the drug is released;

after 8 hours 40-75% of the drug is released;

not less than 50% of the drug is released after 12 hours;

not less than 65% of the drug is released after 16 hours.

37. The sustained-release pharmaceutical formulation as defined in claim 33 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in simulated gastric fluid (pH 1.2) at 37°

C.;

after 2 hours 5-20% of the drug is released;

after 4 hours 15-35% of the drug is released;

after 8 hours 50-65% of the drug is released;

not less than 55% of the drug is released after 12 hours;

not less than 65% of the drug is released after 16 hours.